⌘K

Home/Filings/4/A/0001615219-19-000041

4/A//SEC Filing

Jordan Scott 4/A

Accession 0001615219-19-000041

CIK 0001615219other

View on SEC.gov Company Profile

Filed

Sep 12, 8:00 PM ET

Accepted

Sep 13, 6:31 PM ET

Size

5.5 KB

Accession

0001615219-19-000041

Insider Transaction Report

Form 4/AAmended

Period: 2019-09-10

Salarius Pharmaceuticals, Inc.SLRX

Chief Financial Officer

Transactions

Award
Stock Option (right to buy)
2019-09-10+10,000→ 10,000 total
Exercise: $8.00Exp: 2029-09-10→ Common Stock (10,000 underlying)

Footnotes (1)

[F1]The grant has a 4-year vesting schedule with 25% vesting on September 30, 2020 and 1/12th of the balance vesting on the last day of each calendar quarter thereafter.

Documents

1 file

4
wf-form4a_156841388132729.xml
FORM 4/A

Issuer

Salarius Pharmaceuticals, Inc.

CIK 0001615219

Entity typeother

Related Parties

1

filerCIK 0001769747

Filing Metadata

Form type: 4/A
Filed: Sep 12, 8:00 PM ET
Accepted: Sep 13, 6:31 PM ET
Size: 5.5 KB

View on SEC.gov